Cosmo Pharmaceuticals N.V. (SWX: COPN)

Cosmo Pharmaceuticals Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	54.56	50.28	185.83	198.56	185.94	110.39
Short-Term Investments	19.42	-	52.7	-	-	-
Trading Asset Securities	59.44	-	2.43	23.65	26.92	157.82
Cash & Short-Term Investments	133.41	50.28	240.95	222.21	212.85	268.21
Cash Growth	-39.92%	-79.13%	8.44%	4.40%	-20.64%	-23.25%
Accounts Receivable	23.65	28.45	38.61	24.45	26.99	19.08
Other Receivables	7.63	2.22	2.69	3.23	1.15	1.47
Receivables	31.28	30.67	41.3	27.68	28.14	20.54
Inventory	13.9	14.2	11.5	13.12	5.71	6.14
Prepaid Expenses	-	3.32	3.06	1.96	2.69	2.21
Other Current Assets	5	3.76	9.28	10.88	3.48	5.26
Total Current Assets	183.59	102.23	306.1	275.85	252.87	302.37
Property, Plant & Equipment	27.37	28.59	30.28	30.48	29.3	30.19
Long-Term Investments	3.17	3.29	8.27	49.08	250.61	179.45
Goodwill	24.01	24.01	24.01	24.01	1.44	1.44
Other Intangible Assets	374.46	355.62	360.89	369.31	3.24	21.67
Long-Term Deferred Tax Assets	16.06	17.13	14.68	18.64	8.2	10.01
Long-Term Deferred Charges	-	13.37	5.5	3.42	23.4	27.55
Other Long-Term Assets	9.59	9.75	9.87	9.78	1.81	1.83
Total Assets	638.25	553.98	759.59	805.56	596.16	585.16
Accounts Payable	14.68	8.78	7.59	8.3	5.95	5.52
Accrued Expenses	4.77	6.62	5.9	5.25	2.98	2.97
Current Portion of Long-Term Debt	0.14	0.14	171.07	0.13	0.13	0.13
Current Portion of Leases	0.6	0.76	0.76	0.76	2.81	1.37
Current Income Taxes Payable	11.59	2.17	2.29	3.25	2.46	0.06
Current Unearned Revenue	-	-	-	-	0.14	0.05
Other Current Liabilities	6.11	7.25	7.35	3.55	7.32	5.61
Total Current Liabilities	37.88	25.71	194.95	21.24	21.79	15.71
Long-Term Debt	0.42	0.42	0.56	167.15	163.02	159.11
Long-Term Leases	0.29	0.52	1.21	1.88	2.19	4.23
Long-Term Deferred Tax Liabilities	93.51	94.53	97.1	99.75	6.27	8.82
Other Long-Term Liabilities	0.2	3.2	1.58	2.39	2.39	3.25
Total Liabilities	132.87	124.94	295.8	292.88	196.04	191.43
Common Stock	4.56	4.56	4.56	4.56	3.91	3.91
Additional Paid-In Capital	243.57	243.57	243.57	243.57	84.45	84.45
Retained Earnings	373.53	296.52	310.09	341.16	265.35	272.43
Treasury Stock	-101.82	-101.31	-89.8	-65.56	-49.4	-43.69
Comprensive Income & Other	-21.39	-21.18	-11.49	-18.45	95.82	76.63
Total Common Equity	498.44	422.16	456.93	505.28	400.13	393.73
Minority Interest	6.94	6.88	6.86	7.4	-	-
Shareholders' Equity	505.39	429.04	463.79	512.68	400.13	393.73
Total Liabilities & Equity	638.25	553.98	759.59	805.56	596.16	585.16
Total Debt	1.46	1.84	173.6	169.92	168.14	164.84
Net Cash (Debt)	131.96	48.44	67.36	52.29	44.71	103.37
Net Cash Growth	183.60%	-28.09%	28.81%	16.96%	-56.75%	-45.96%
Net Cash Per Share	8.19	3.01	4.10	3.09	3.09	7.06
Filing Date Shares Outstanding	16.05	16.05	16.26	16.71	14.43	14.52
Total Common Shares Outstanding	16.05	16.05	16.26	16.71	14.43	14.52
Working Capital	145.72	76.51	111.15	254.61	231.08	286.66
Book Value Per Share	31.06	26.30	28.10	30.24	27.72	27.12
Tangible Book Value	99.98	42.53	72.04	111.96	395.44	370.63
Tangible Book Value Per Share	6.23	2.65	4.43	6.70	27.40	25.53
Land	-	25.01	24.97	24.02	22.79	23.27
Machinery	-	47.95	45.14	40.16	37.99	35.05
Construction In Progress	-	-	-	1.67	0.1	0.41

Source: S&P Capital IQ. Standard template. Financial Sources.